Abstract
Allergic disorders are a group of multifactorial diseases increasing in prevalence in recent years. Steroids remain the cornerstone of symptomatic treatment, but advances in molecular biology have led to a better understanding of the pathogenesis of allergic diseases and multiple medications; especially monoclonal antibodies have been developed with different therapeutic targets.
Omalizumab (Anti-IgE) and mepolizumab (Anti-IL5) are some of the biological agents already available for the treatment of asthma and other allergic diseases, but many other molecules are currently being studied in clinical trials. In this chapter we review the different monoclonal antibodies that are being studied in allergic diseases with emphasis on the evidence of their use in asthma.
Keywords: Asthma, allergy, allergen, immunotherapy, immunomodulation, monoclonal antibodies, mepolizumab, omalizumab, immunoglobulin, sensitization.
Related Journals
Current Dentistry
Current Traditional Medicine
Adolescent Psychiatry
New Emirates Medical Journal
Current Probiotics
Endocrine, Metabolic & Immune Disorders - Drug Targets
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)
Current Drug Targets - Immune, Endocrine & Metabolic Disorders
Recent Advances in Inflammation & Allergy Drug Discovery
Current Respiratory Medicine Reviews
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents